# Ipamorelin vs GHRP-2: Selectivity vs Potency in Ghrelin-Receptor GH Secretagogue Research

> Research comparison of ipamorelin (selective GHSR-1a agonist, no cortisol/prolactin/ACTH effect) vs GHRP-2 (pralmorelin; stronger GH pulse with off-target endocrine effects and appetite stimulation).

Source: https://peptpedia.org/compare/ipamorelin-vs-ghrp-2 | Published: 2026-07-18 | Last updated: 2026-07-18

## Executive Summary

Ipamorelin and GHRP-2 (pralmorelin) are both growth hormone secretagogues acting through the ghrelin receptor (GHSR-1a), but they sit at opposite ends of the class's selectivity spectrum. Ipamorelin was characterized by its developer as the first selective GH secretagogue: in preclinical and clinical characterization it released GH dose-dependently without significantly affecting ACTH, cortisol, or prolactin. GHRP-2 produces a strong GH pulse — in human volunteers its GH response exceeded that of GHRH and matched hexarelin — but is not fully specific, raising prolactin, ACTH, and cortisol, and it significantly increases food intake through its ghrelin-mimetic action. The comparison is therefore not about which stimulates more GH, but about how much off-target endocrine activity a research design can tolerate.

## Side-by-Side Comparison

| Property | Ipamorelin | GHRP-2 |
| --- | --- | --- |
| Drug Class | Selective GHRP (pentapeptide) | GHRP (hexapeptide; pralmorelin, KP-102) |
| Molecular Formula | C38H49N9O5 | C45H55N9O6 |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 |
| Primary Receptor | GHSR-1a (ghrelin receptor) | GHSR-1a (ghrelin receptor) |
| GH Pulse Potency | Strong, dose-dependent | Strong; exceeded GHRH, matched hexarelin in humans (PMID: 9285939) |
| Cortisol / ACTH Effect | None significant at research doses (PMID: 9849822) | Increases ACTH/cortisol, similar in magnitude to hCRH (PMID: 9285939) |
| Prolactin Effect | None significant (PMID: 9849822) | Slight increase, less than TRH (PMID: 9285939) |
| Appetite Effect | Minimal | Significant; +35.9% food intake in men (PMID: 15699539) |
| Human Half-Life | ~2 hours; GH peak at 0.67 h (PMID: 10496658) | Short; characterized mainly by infusion studies |
| Human Clinical Data | PK/PD modeling in healthy volunteers | Endocrine challenge studies; diagnostic development in Japan |
| Clinical Development | Investigational | Advanced as GH-deficiency diagnostic (KP-102D, Japan); US program discontinued (PMID: 15230633) |
| Selectivity Rank in Class | Highest among GHRPs | Moderate (less selective than ipamorelin, more than GHRP-6) |
| Evidence Level | Moderate (human PK + selectivity data) | Moderate (human endocrine and feeding studies) |

## Mechanism: Same Receptor, Different Selectivity

Both [ipamorelin](https://peptpedia.org/peptide/ipamorelin) and [GHRP-2](https://peptpedia.org/peptide/ghrp-2) belong to the growth hormone-releasing peptide class that originated with Bowers and colleagues' 1984 description of a synthetic hexapeptide that acts on the pituitary to specifically release GH (PMID: 6714155). Both exert their primary action through GHSR-1a, the ghrelin receptor, expressed on pituitary somatotrophs and hypothalamic neurons. Receptor activation triggers phospholipase C signaling and a brisk, pulse-type release of stored GH — mechanistically distinct from the GHRH receptor pathway, which explains the synergy observed when GHRPs are combined with GHRH analogs.

**Ipamorelin's distinction is what it does not do.** In the characterization program published by Raun and colleagues (PMID: 9849822), ipamorelin — a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) — released GH with potency comparable to GHRP-6 in vitro and in vivo, yet unlike the earlier GHRPs it did not significantly increase ACTH, cortisol, or prolactin, and it preserved the pulsatile pattern of GH secretion. The authors designated it the first selective growth hormone secretagogue on that basis.

**GHRP-2 trades selectivity for a broader endocrine footprint.** As a hexapeptide ghrelin mimetic, it engages the same GHSR-1a receptor but its downstream effects in humans extend beyond GH: the Arvat study (PMID: 9285939) documented measurable prolactin, ACTH, and cortisol responses, and its ghrelin-like activity extends to appetite regulation (PMID: 15699539). At the receptor level both molecules are GHSR-1a agonists; the selectivity difference emerges in the pattern of neuroendocrine responses downstream — including hypothalamic circuits governing stress hormones and hunger — rather than in GH pulse initiation itself. Whether that gap reflects receptor-level signaling bias, differential tissue distribution, or engagement of distinct neuronal populations has never been resolved, and no published study has mapped ipamorelin's selectivity to a single molecular event.

## Clinical Evidence: GH Potency vs Endocrine Side Effects

**GHRP-2 in humans (Arvat 1997, PMID: 9285939):** In 6 healthy young adults, intravenous GHRP-2 at 1 and 2 µg/kg produced a strong, dose-related GH response that was significantly higher than the response to GHRH 1 µg/kg (P<0.05) and similar to hexarelin. The same study documented the off-target profile: GHRP-2 and hexarelin induced similar increases in prolactin, ACTH, and cortisol — the prolactin response was lower than that to TRH (P<0.01), while the ACTH/cortisol response was comparable in magnitude to hCRH. The authors concluded these peptides are not fully specific. In elderly subjects (66-73 years), the GH response was blunted relative to young adults, consistent with age-related decline in the GH axis.

**GHRP-2 and appetite (Laferrère 2005, PMID: 15699539):** Seven lean healthy men received subcutaneous GHRP-2 infusion (1 µg/kg/h for 270 minutes) or saline, then ate an ad libitum buffet meal. Every subject ate more under GHRP-2: intake rose 35.9 ± 10.9% (136.0 ± 13.0 vs 101.3 ± 10.5 kJ/kg, P=0.008), while serum GH rose as expected (AUC 5550 ± 1090 vs 412 ± 161 µg/L/240 min, P=0.003). This was the first demonstration that GHRP-2, like ghrelin itself, stimulates food intake in humans — a direct confound for any metabolic or body-composition research design.

**Ipamorelin in humans:** The human evidence for ipamorelin centers on pharmacokinetic-pharmacodynamic characterization (PMID: 10496658) and the selectivity profile established in the Raun program (PMID: 9849822). No published human study has directly compared ipamorelin against GHRP-2; the potency contrast is inferred from each peptide's separate comparison against GHRH and other GHRPs.

**GHRP-2's development history (PMID: 15230633):** As pralmorelin (KP-102), GHRP-2 was developed as a diagnostic agent for GH deficiency — its ability to raise GH regardless of sex, obesity, or age supported a receiver-operating cut-off of 15.0 µg/L peak GH for distinguishing deficiency — and advanced toward approval in Japan, while a US development program was discontinued. The diagnostic application exploited precisely the property that complicates metabolic research use: a robust, reproducible GH pulse even in elderly and obese subjects, whose response to weaker stimuli is blunted.

## Pharmacokinetics and Research Dosing Context

**Ipamorelin (human PK/PD, PMID: 10496658):** Gobburu and colleagues administered five escalating intravenous infusion rates (4.21 to 140.45 nmol/kg over 15 minutes) to healthy male volunteers, eight per dose level. Pharmacokinetics were dose-proportional with a short terminal half-life of 2 hours, clearance of 0.078 L/h/kg, and steady-state distribution volume of 0.22 L/kg. Each dose produced a single episode of GH release peaking at 0.67 hours and declining exponentially to negligible levels; the modeled half-maximal stimulatory concentration was 214 nmol/L with a maximal GH production rate of 694 mIU/L/h. Every injection therefore yields one clean, self-limited GH pulse with no accumulation between doses.

**GHRP-2:** Human exposure data derive mainly from bolus and infusion endocrine studies rather than formal PK modeling. In the Laferrère protocol, a 1 µg/kg/h subcutaneous infusion sustained GH elevation across the 270-minute study window (PMID: 15699539), and Arvat used single intravenous boluses of 1-2 µg/kg for acute pituitary stimulation (PMID: 9285939). Like other GHRPs it is a short-acting peptide cleared within hours; published research uses single or repeated daily subcutaneous or intravenous administration. GHRP-2 is also unusual in the class for reported oral activity — the pralmorelin program evaluated subcutaneous, buccal, oral, and depot formulations (PMID: 15230633) — although the controlled human endocrine studies cited here used parenteral administration, and no formal human bioavailability comparison across routes has been published.

**Design implications:** Both peptides suit acute-pulse experimental designs, but their kinetics interact with selectivity. Ipamorelin's 2-hour half-life and isolated GH pulse make repeated-dose designs straightforward to interpret — each dose maps to one GH episode with no hormonal carryover. GHRP-2's simultaneous ACTH/cortisol and prolactin responses mean that repeated dosing superimposes repeated hypothalamic-pituitary-adrenal axis activation, and its orexigenic effect accumulates with chronic administration — both must be controlled for in study design. Neither peptide has an established human therapeutic dosing regimen; all published use is investigational.

## Safety and Tolerability Profile

**Ipamorelin:** Its safety rationale rests on the selectivity data (PMID: 9849822): no significant ACTH, cortisol, or prolactin elevation at GH-releasing research doses, avoiding the stress-axis and lactotrope activation seen with non-selective GHRPs. Human volunteer studies reported good tolerability, with transient head rush or lightheadedness noted in research contexts. Preclinical toxicology and the peptide's advancement into human testing support a clean acute profile, but chronic administration safety — months of repeated GH pulses — has never been formally studied. No long-term human safety trials exist.

**GHRP-2:** Acute human studies were well tolerated, but the pharmacological profile includes predictable off-target effects:

- **HPA-axis activation:** ACTH and cortisol rises comparable to hCRH at GH-releasing doses (PMID: 9285939) — a confound in stress-sensitive or metabolic endpoints

- **Prolactin elevation:** Smaller than TRH-induced release but measurable (PMID: 9285939)

- **Orexigenic effect:** A 35.9% acute increase in food intake in healthy men (PMID: 15699539) — directly counterproductive in weight-management research designs

- **Blunted response with age:** Reduced GH release in elderly subjects, relevant to interpretation of age-stratified studies (PMID: 9285939)

**Shared limitations:** Neither peptide has completed long-term human safety evaluation. Chronic GH/IGF-1 elevation carries the same theoretical proliferative concerns as any GH secretagogue. GHRPs as a class are prohibited in sport under the WADA Prohibited List (S2, growth hormone releasing factors). Both are sold as research chemicals outside any approved indication, with the identity and purity risks that unregulated supply entails; no comparative safety trial between the two exists. For chronic designs, GHRP-2's appetite effect doubles as a tolerability caveat: increased caloric intake is a pharmacological action of the drug, not incidental background noise.

## Research Verdict: Selectivity Is the Deciding Variable

**Ipamorelin suits research questions requiring:**

- Isolated GH-axis stimulation without cortisol, ACTH, or prolactin confounds (PMID: 9849822)

- Clean single-pulse GH pharmacodynamics with human PK/PD modeling behind them (PMID: 10496658)

- Combination designs with GHRH analogs, where an uncontaminated GHSR-1a signal preserves interpretability

- Metabolic or body-composition endpoints where appetite stimulation would invalidate the design

**GHRP-2 suits research questions requiring:**

- A maximal-amplitude GH pulse — its human GH response exceeded GHRH and matched hexarelin (PMID: 9285939)

- Ghrelin-pathway biology beyond GH: appetite, meal initiation, and energy-intake studies (PMID: 15699539)

- Pituitary reserve testing and diagnostic research, its most developed clinical application (PMID: 15230633)

- Comparative secretagogue pharmacology across the GHRP class (GHRP-6 → GHRP-2 → hexarelin → ipamorelin)

**What the evidence does not show:** No head-to-head human trial has compared ipamorelin and GHRP-2 for GH output, tolerability, or any downstream endpoint. The potency ordering is inferred from each compound's separate comparisons against common reference stimuli. Claims that one is universally "stronger" misread the data — ipamorelin matches GHRP-class GH release while stripping away the prolactin, ACTH/cortisol, and appetite effects that define GHRP-2's broader profile.

**Bottom line for study design:** when the research question is "GH and only GH," the evidence favors ipamorelin's selectivity; when the question involves ghrelin-system effects in full — including feeding behavior — GHRP-2 is the more informative tool. Both remain short-acting investigational peptides with no approved indication, and any chronic-dosing protocol for either should treat the absence of long-term human data as a primary design limitation rather than an afterthought, with endocrine monitoring appropriate to the off-target profile documented in humans.

## Frequently Asked Questions

### Why is ipamorelin called the selective GHRP?

Ipamorelin was characterized by Raun and colleagues as the first selective growth hormone secretagogue because it releases GH with potency comparable to earlier GHRPs without significantly raising ACTH, cortisol, or prolactin (PMID: 9849822). GHRP-2, GHRP-6, and hexarelin all produce measurable off-target endocrine effects in humans, so ipamorelin's GH-only profile makes it the preferred tool when experimental confounds from stress hormones or prolactin must be avoided.

### Does GHRP-2 increase cortisol and prolactin?

Yes. In a controlled human study of 6 healthy adults, intravenous GHRP-2 at 1-2 µg/kg increased prolactin, ACTH, and cortisol in addition to GH. The prolactin rise was smaller than that produced by TRH, but the ACTH/cortisol response was comparable in magnitude to hCRH (PMID: 9285939). The study's authors concluded GHRP-2 is not fully specific — the key pharmacological difference from ipamorelin.

### Does GHRP-2 stimulate appetite?

Yes, significantly. When 7 lean healthy men received a subcutaneous GHRP-2 infusion (1 µg/kg/h over 270 minutes), every subject ate more at a subsequent buffet meal — intake rose an average of 35.9% versus saline (PMID: 15699539). GHRP-2 is a ghrelin mimetic, and ghrelin's second major action after GH release is appetite stimulation. Ipamorelin, in contrast, has minimal reported effect on hunger at research doses.

### Which releases more growth hormone, ipamorelin or GHRP-2?

No head-to-head human trial exists, so a definitive ranking is not possible. GHRP-2's human GH response exceeded that of GHRH and matched hexarelin at 1-2 µg/kg intravenously (PMID: 9285939). Ipamorelin's preclinical characterization found GH-releasing potency comparable to GHRP-6 (PMID: 9849822), and its human PK/PD study modeled a robust single GH pulse per dose (PMID: 10496658). The practical difference is not peak GH amplitude but everything else that accompanies the pulse.

### Was GHRP-2 ever developed as a drug?

Yes, under the name pralmorelin (KP-102). Originating from the Tulane University (Cyril Bowers) and Polygen programs, it was developed by Kaken in Japan as a diagnostic for growth hormone deficiency — a GH peak cut-off of 15.0 µg/L was derived to distinguish deficient patients from healthy controls — and reached late-stage development there, with a separate Phase 2 program for short stature. A US development program was discontinued (PMID: 15230633). It is not approved as a therapeutic in any major market.

## References

1. Raun K, Hansen BS, Johansen NL, et al.. "Ipamorelin, the first selective growth hormone secretagogue." *European journal of endocrinology* (1998). [PMID 9849822](https://pubmed.ncbi.nlm.nih.gov/9849822/) | [doi:10.1530/eje.0.1390552](https://doi.org/10.1530/eje.0.1390552)
2. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers." *Pharmaceutical research* (1999). [PMID 10496658](https://pubmed.ncbi.nlm.nih.gov/10496658/) | [doi:10.1023/a:1018955126402](https://doi.org/10.1023/a:1018955126402)
3. Arvat E, di Vito L, Maccagno B, et al.. "Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH." *Peptides* (1997). [PMID 9285939](https://pubmed.ncbi.nlm.nih.gov/9285939/) | [doi:10.1016/s0196-9781(97)00016-8](https://doi.org/10.1016/s0196-9781(97)00016-8)
4. Laferrère B, Abraham C, Russell CD, Bowers CY. "Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men." *The Journal of clinical endocrinology and metabolism* (2005). [PMID 15699539](https://pubmed.ncbi.nlm.nih.gov/15699539/) | [doi:10.1210/jc.2004-1719](https://doi.org/10.1210/jc.2004-1719)
5. Adis International Limited. "Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN." *Drugs in R&D* (2004). [PMID 15230633](https://pubmed.ncbi.nlm.nih.gov/15230633/) | [doi:10.2165/00126839-200405040-00011](https://doi.org/10.2165/00126839-200405040-00011)
6. Bowers CY, Momany FA, Reynolds GA, Hong A. "On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone." *Endocrinology* (1984). [PMID 6714155](https://pubmed.ncbi.nlm.nih.gov/6714155/) | [doi:10.1210/endo-114-5-1537](https://doi.org/10.1210/endo-114-5-1537)

---

This content is for educational and research purposes only. It is not medical advice, and the compounds covered are research chemicals not approved for human use unless explicitly stated otherwise.

Cite this page: Peptpedia — Research Peptide Encyclopedia, https://peptpedia.org